

Mark A Lovell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4713421/publications.pdf>

Version: 2024-02-01

55
papers

5,824
citations

94433

37
h-index

155660

55
g-index

57
all docs

57
docs citations

57
times ranked

6215
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxidative DNA damage in mild cognitive impairment and late-stage Alzheimer's disease. <i>Nucleic Acids Research</i> , 2007, 35, 7497-7504.	14.5	433
2	Increased Nuclear DNA Oxidation in the Brain in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 1998, 71, 2034-2040.	3.9	421
3	Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures. <i>Neurobiology of Aging</i> , 2001, 22, 187-194.	3.1	410
4	Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease. <i>Neurobiology of Aging</i> , 2006, 27, 1094-1099.	3.1	342
5	Lipid peroxidation is an early event in the brain in amnesic mild cognitive impairment. <i>Annals of Neurology</i> , 2005, 58, 730-735.	5.3	264
6	Increased DNA Oxidation and Decreased Levels of Repair Products in Alzheimer's Disease Ventricular CSF. <i>Journal of Neurochemistry</i> , 1999, 72, 771-776.	3.9	254
7	Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment. <i>Journal of Neurochemistry</i> , 2006, 96, 825-832.	3.9	243
8	Decrease in Peptide Methionine Sulfoxide Reductase in Alzheimer's Disease Brain. <i>Journal of Neurochemistry</i> , 2002, 73, 1660-1666.	3.9	232
9	Association of Antioxidant Supplement Use and Dementia in the Prevention of Alzheimer's Disease by Vitamin E and Selenium Trial (PREADVISE). <i>JAMA Neurology</i> , 2017, 74, 567.	9.0	215
10	Oxidative damage in mild cognitive impairment and early Alzheimer's disease. <i>Journal of Neuroscience Research</i> , 2007, 85, 3036-3040.	2.9	212
11	Induction of hyperphosphorylated tau in primary rat cortical neuron cultures mediated by oxidative stress and glycogen synthase kinase-3. <i>Journal of Alzheimer's Disease</i> , 2005, 6, 659-671.	2.6	170
12	Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. <i>Brain Research</i> , 2000, 855, 116-123.	2.2	162
13	University of Kentucky Sanders-Brown Healthy Brain Aging Volunteers: Donor Characteristics, Procedures and Neuropathology. <i>Current Alzheimer Research</i> , 2012, 9, 724-733.	1.4	146
14	DNA Oxidation in Alzheimer's Disease. <i>Antioxidants and Redox Signaling</i> , 2006, 8, 2039-2045.	5.4	133
15	Biomarkers of lipid peroxidation in Alzheimer disease (AD): an update. <i>Archives of Toxicology</i> , 2015, 89, 1035-1044.	4.2	132
16	Laser microprobe analysis of brain aluminum in Alzheimer' disease. <i>Annals of Neurology</i> , 1993, 33, 36-42.	5.3	122
17	Oxidatively modified nucleic acids in preclinical Alzheimer's disease (PCAD) brain. <i>Mechanisms of Ageing and Development</i> , 2011, 132, 443-448.	4.6	110
18	Acrolein, a product of lipid peroxidation, inhibits glucose and glutamate uptake in primary neuronal cultures. <i>Free Radical Biology and Medicine</i> , 2000, 29, 714-720.	2.9	109

#	ARTICLE	IF	CITATIONS
19	Identification and characterization of OGG1 mutations in patients with Alzheimer's disease. <i>Nucleic Acids Research</i> , 2007, 35, 2759-2766.	14.5	105
20	Altered 8-oxoguanine glycosylase in mild cognitive impairment and late-stage Alzheimer's disease brain. <i>Free Radical Biology and Medicine</i> , 2008, 45, 813-819.	2.9	99
21	Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. <i>Free Radical Biology and Medicine</i> , 2008, 45, 219-230.	2.9	95
22	Oxidatively modified RNA in mild cognitive impairment. <i>Neurobiology of Disease</i> , 2008, 29, 169-175.	4.4	93
23	Nucleic acid oxidation: an early feature of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2014, 128, 294-304.	3.9	88
24	Alterations of Zinc Transporter Proteins ZnT1, ZnT4 and ZnT6 in Preclinical Alzheimer's Disease Brain. <i>Brain Pathology</i> , 2010, 20, 343-350.	4.1	84
25	Alterations in zinc transporter protein-1 (ZnT-1) in the brain of subjects with mild cognitive impairment, early, and late-stage Alzheimer's disease. <i>Neurotoxicity Research</i> , 2005, 7, 265-271.	2.7	82
26	Survival of hippocampal and cortical neurons in a mixture of MEM+ and B27-supplemented neurobasal medium. <i>Free Radical Biology and Medicine</i> , 2000, 28, 665-672.	2.9	81
27	A Potential Role for Alterations of Zinc and Zinc Transport Proteins in the Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2009, 16, 471-483.	2.6	80
28	Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression. <i>Neurobiology of Aging</i> , 2012, 33, 1034-1044.	3.1	76
29	Development of a Method for Quantification of Acrolein-Deoxyguanosine Adducts in DNA Using Isotope Dilution-Capillary LC/MS/MS and Its Application to Human Brain Tissue. <i>Analytical Chemistry</i> , 2005, 77, 5982-5989.	6.5	75
30	4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. <i>Neuroscience Letters</i> , 2004, 356, 155-158.	2.1	68
31	Organoselenium (Sel-Plex diet) decreases amyloid burden and RNA and DNA oxidative damage in APP/PS1 mice. <i>Free Radical Biology and Medicine</i> , 2009, 46, 1527-1533.	2.9	64
32	Detection and Quantification of Endogenous Cyclic DNA Adducts Derived from trans-4-Hydroxy-2-nonenal in Human Brain Tissue by Isotope Dilution Capillary Liquid Chromatography Nanoelectrospray Tandem Mass Spectrometry. <i>Chemical Research in Toxicology</i> , 2006, 19, 710-718.	3.3	55
33	Quantitative Proteomic Analysis of Mitochondria from Primary Neuron Cultures Treated with Amyloid Beta Peptide. <i>Neurochemical Research</i> , 2005, 30, 113-122.	3.3	54
34	Analysis of Derivatized Biogenic Aldehydes by LC Tandem Mass Spectrometry. <i>Analytical Chemistry</i> , 2005, 77, 3383-3389.	6.5	48
35	Serum Zinc in the Progression of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2008, 15, 443-450.	2.6	47
36	Elevated Zinc Transporter-6 in Mild Cognitive Impairment, Alzheimer Disease, and Pick Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 489-498.	1.7	43

#	ARTICLE	IF	CITATIONS
37	Multiregional analysis of global 5-methylcytosine and 5-hydroxymethylcytosine throughout the progression of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2017, 140, 383-394.	3.9	42
38	Wilms' tumor suppressor (WT1) is a mediator of neuronal degeneration associated with the pathogenesis of Alzheimer's disease. <i>Brain Research</i> , 2003, 983, 84-96.	2.2	36
39	Quantitative Changes in the Mitochondrial Proteome from Subjects with Mild Cognitive Impairment, Early Stage, and Late Stage Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 325-339.	2.6	36
40	Quantitative Proteomic Analysis of Mitochondria in Aging PS-1 Transgenic Mice. <i>Cellular and Molecular Neurobiology</i> , 2009, 29, 649-664.	3.3	33
41	Amyloid Beta Peptide, 4-Hydroxynonenal and Apoptosis. <i>Current Alzheimer Research</i> , 2006, 3, 359-364.	1.4	32
42	Calcium Channel Blockers, Progression to Dementia, and Effects on Amyloid Beta Peptide Production. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-9.	4.0	32
43	A potential role for zinc alterations in the pathogenesis of Alzheimer's disease. <i>BioFactors</i> , 2012, 38, 98-106.	5.4	29
44	Single-Base Resolution Mapping of 5-Hydroxymethylcytosine Modifications in Hippocampus of Alzheimer's Disease Subjects. <i>Journal of Molecular Neuroscience</i> , 2017, 63, 185-197.	2.3	28
45	RNA Oxidation Adducts 8-OHG and 8-OHA Change with A β 242 Levels in Late-Stage Alzheimer's Disease. <i>PLoS ONE</i> , 2011, 6, e24930.	2.5	23
46	METHODOLOGICAL DEVELOPMENTS FOR APPLICATION TO THE STUDY OF PHYSIOLOGICAL BORON AND TO BORON NEUTRON CAPTURE THERAPY. <i>Instrumentation Science and Technology</i> , 2001, 19, 623-657.	0.8	21
47	Ectopic Expression of Musashi-1 in Alzheimer Disease and Pick Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 675-680.	1.7	19
48	Procedure for the isolation of mitochondria, cytosolic and nuclear material from a single piece of neurological tissue for high-throughput mass spectral analysis. <i>Journal of Neuroscience Methods</i> , 2011, 197, 279-282.	2.5	17
49	A novel method for the rapid detection of post-translationally modified visinin-like protein 1 in rat models of brain injury. <i>Brain Injury</i> , 2018, 32, 363-380.	1.2	9
50	4-Hydroxyhexenal (HHE) Impairs Glutamate Transport in Astrocyte Cultures. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 139-146.	2.6	8
51	A Novel Small Molecule Modulator of Amyloid Pathology. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 273-287.	2.6	6
52	Similarities and Differences Between Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 219-219.	2.6	1
53	Pharmacokinetic and metabolic analysis of an Alzheimer's disease therapeutic in rat serum via microfluidic CZE-MS. <i>Biomedical Chromatography</i> , 2021, , e5243.	1.7	1
54	Zinc and Zinc Transport and Sequestration Proteins in the Brain in the Progression of Alzheimer's Disease. <i>Advances in Neurobiology</i> , 2011, , 669-693.	1.8	1

#	ARTICLE	IF	CITATIONS
55	Memories of Dr. William R. Markesbery. <i>NeuroMolecular Medicine</i> , 2011, 13, 15-16.	3.4	0